75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 66

75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial

75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial

Background/Significance

Early-stage breast cancer is commonly treated with breast-conserving surgery (BCS) followed by whole breast irradiation (WBI). A radiation boost to the tumor bed is also recommended in some cases, is dependent on patient age and disease characteristics, and is usually delivered following BCS and WBI. We conducted a prospective, phase 2 clinical trial (NCT04871516) in which the radiation boost was delivered preoperatively instead of postoperatively, the first results of which have been previously published. Due to concerns that the preoperative radiation boost could possibly alter the genomic profile of the tumor, we compared the 21-gene assay results (Oncotype DX Breast Recurrence Score) before and after the boost, to see if a change may have altered systemic therapy.

Materials and Methods

Patients received a preoperative boost of 13.32 Gy in 4 daily fractions, followed by BCS 1 to 3 weeks after, followed by WBI of 36.63 Gy in 11 daily fractions 3 to 8 weeks after surgery. A total of 55 patients were enrolled in the trial. We randomly selected 17 patients to compare the 21-gene assay results before and after the boost. We used paired Student’s t-test to see whether the difference between the 2 sets of scores is statistically significant.

Results

Tissue was sufficient to run the assay on the core needle biopsy and the lumpectomy specimens in 15 patients. All patients had clinically negative axillary nodes. The median age at diagnosis was 68 years (range, 53-79). Average tumor size was 13.15 mm (range, 7-21). There were 3 lobular, 1 mucinous, and 11 ductal invasive carcinomas. All tumors were hormone receptor–positive and HER2-negative. The mean 21-gene assay result prior to the radiation boost was 12 (± SD, 7.92), and after was 13.47 (± SD 6.93). Paired Student’s t-test showed no significant difference between the pre- and postradiation results (t = 0.5399, P = .6). In 9 of 15 (60%) patients, the results of the 21-gene assay slightly increased after the boost by an average of 4.78 points (± SD, 2.05), and in 6 of 15 (40%), they slightly decreased by an average of 3.5 points (± SD, 2.74). In none of these 15 patients would the preoperative boost have altered systemic therapy.

Conclusion

In this cohort of patients from our preoperative radiation boost trial, results of the 21-gene assay were not significantly changed after the radiation boost. This indicates that, in this protocol, preoperative radiation boost would likely not alter systemic therapy decisions.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Related Content